8,049 research outputs found

    Super-Twisting Hybrid Control for Ship-Borne PMSM

    Get PDF

    Constraining the ellipticity and frequency of binary neutron star remnant via its gravitational-wave and electromagnetic radiations

    Full text link
    The nature of the merger remnant of binary neutron star (BNS) remains an open question. From the theoretical point of view, one possible outcome is a supra-massive neutron star (SMNS), which is supported by rigid rotation and through its survival of hundreds of seconds before collapsing into a black hole (BH). If this is the case, the SMNS can emit continuous gravitational waves (GW) and electromagnetic (EM) radiation, particularly in the X-ray band. In this work, the ellipticity and initial frequency of SMNS are constrained with a Bayesian framework using simulated X-ray and GW signals, which could be detected by The Transient High Energy Sky and Early Universe Surveyor (THESEUS) and Einstein Telescope (ET), respectively. We found that only considering the X-ray emission can not completely constrain the initial frequency and ellipticity of the SMNS, but it can reduce the ranges of the parameters. Afterwards, we can use the posterior distribution of the X-ray parameter estimates as a prior for the GW parameter estimates. It was found that the 95%\% credible region of the joint X-ray-GW analysis was about 10510^5 times smaller than that of the X-ray analysis alone.Comment: Accepted by MNRA

    Efficient Sunlight-Induced Methylene Blue Removal over One-Dimensional Mesoporous Monoclinic BiVO4 Nanorods

    Get PDF
    Sunlight-driven mesoporous BiVO4 nanorods with monoclinic structure have been successfully synthesized via a simple hydrothermal method. The as-prepared one-dimensional BiVO4 nanorods exhibited high specific surface area due to their unique mesoporous structure. The mesoporous BiVO4 nanorods possessed strong photoabsorption properties in the visible light region as well as the ultravisible region, and the band gap was estimated to be ca. 2.18 eV. The photocatalytic activities were evaluated by decolorization of methylene blue under sunlight irradiation. Photocatalytic tests demonstrated that the decolorization rate of as-prepared mesoporous BiVO4 nanorods was even up to 98.8% in 180 min, much better than that prepared by solid-state reaction (23.1%) and the commercial TiO2 (Degussa P25) (14.2%) under the same conditions, due to their higher specific surface area and appropriate band gap. Moreover, the unique BiVO4 nanorods exhibit high stability after five photocatalytic degradation recycles

    Synergistic binding of actinomycin D and echinomycin to DNA mismatch sites and their combined anti-tumour effects

    Get PDF
    Combination cancer chemotherapy is one of the most useful treatment methods to achieve a synergistic effect and reduce the toxicity of dosing with a single drug. Here, we use a combination of two well-established anticancer DNA intercalators, actinomycin D (ActD) and echinomycin (Echi), to screen their binding capabilities with DNA duplexes containing different mismatches embedded within Watson-Crick base-pairs. We have found that combining ActD and Echi preferentially stabilised thymine-related T:T mismatches. The enhanced stability of the DNA duplex-drug complexes is mainly due to the cooperative binding of the two drugs to the mismatch duplex, with many stacking interactions between the two different drug molecules. Since the repair of thymine-related mismatches is less efficient in mismatch repair (MMR)-deficient cancer cells, we have also demonstrated that the combination of ActD and Echi exhibits enhanced synergistic effects against MMR-deficient HCT116 cells and synergy is maintained in a MMR-related MLH1 gene knockdown in SW620 cells. We further accessed the clinical potential of the two-drug combination approach with a xenograft mouse model of a colorectal MMR-deficient cancer, which has resulted in a significant synergistic anti-tumour effect. The current study provides a novel approach for the development of combination chemotherapy for the treatment of cancers related to DNA-mismatches
    corecore